CN116849356A - 一种用于缓解肥胖的可食用组合物及其制备方法 - Google Patents
一种用于缓解肥胖的可食用组合物及其制备方法 Download PDFInfo
- Publication number
- CN116849356A CN116849356A CN202310829449.8A CN202310829449A CN116849356A CN 116849356 A CN116849356 A CN 116849356A CN 202310829449 A CN202310829449 A CN 202310829449A CN 116849356 A CN116849356 A CN 116849356A
- Authority
- CN
- China
- Prior art keywords
- parts
- edible composition
- weight
- fucoxanthin
- resveratrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 208000008589 Obesity Diseases 0.000 title claims abstract description 13
- 235000020824 obesity Nutrition 0.000 title claims abstract description 13
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 20
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 20
- 229920001353 Dextrin Polymers 0.000 claims abstract description 20
- 239000004375 Dextrin Substances 0.000 claims abstract description 20
- 229920001503 Glucan Polymers 0.000 claims abstract description 20
- 229920001202 Inulin Polymers 0.000 claims abstract description 20
- 240000000249 Morus alba Species 0.000 claims abstract description 20
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 20
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Chemical group OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 20
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 20
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 20
- 239000004410 anthocyanin Substances 0.000 claims abstract description 20
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 20
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 20
- 235000019425 dextrin Nutrition 0.000 claims abstract description 20
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical group C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims abstract description 20
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 20
- 229940029339 inulin Drugs 0.000 claims abstract description 20
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 20
- 239000005017 polysaccharide Substances 0.000 claims abstract description 20
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 20
- 229940016667 resveratrol Drugs 0.000 claims abstract description 20
- 229940054810 white kidney bean extract Drugs 0.000 claims abstract description 20
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 244000269722 Thea sinensis Species 0.000 claims abstract 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000945 filler Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 235000019411 steviol glycoside Nutrition 0.000 claims description 3
- 229930182488 steviol glycoside Natural products 0.000 claims description 3
- 150000008144 steviol glycosides Chemical class 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 16
- 235000019786 weight gain Nutrition 0.000 abstract description 10
- 230000004584 weight gain Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000036186 satiety Effects 0.000 abstract description 4
- 235000019627 satiety Nutrition 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 235000019577 caloric intake Nutrition 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 13
- 241001122767 Theaceae Species 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000195974 Selaginella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- -1 preferably Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种用于缓解肥胖的组合物及其制备方法。本发明所述组合物包括如下组分:岩藻黄质、白藜芦醇、中链甘油三酯、白芸豆提取物、玳玳花粉、桑葚花色苷、茶多糖、菊粉、燕麦葡聚糖、抗性糊精。本发明将各种功能的原料进行融合,并通过有效成分之间的协同作用,在增加饱腹感的同时刺激脂肪燃烧、降低热量摄取、减少脂肪吸收,对减缓体重增长、降低血清中的甘油三酯和胆固醇具有协同增效的作用。
Description
技术领域
本发明涉及食品和医药技术领域,尤其是涉及一种用于缓解肥胖的可食用组合物及其制备方法。
背景技术
肥胖是一个严重的公共健康问题,在全球的患病率很高,而且与慢性疾病有关,肥胖能增加糖尿病、心脑血管疾病、痛风、脂肪肝、呼吸系统疾病、各种类型的癌症、神经退行性疾病等的发生几率,带来严重的健康负担和经济负担。
目前主流的减肥方式都有副作用,比如药物疗法会引起肝肾损伤、运动疗法难以坚持且需要时间,因此,利用具有减肥潜能的天然物质,开发高效、安全的抗肥胖药物,对于防治肥胖具有重大意义。
发明内容
本发明的目的在于运用天然活性物质、结合多种减肥机理提供一种用于缓解肥胖的组合物。
本发明的上述目的通过以下的技术方案来实现:
一方面,本发明提供一种用于减缓肥胖的可食用组合物,所述组合物包括如下组分:岩藻黄质、白藜芦醇、中链甘油三酯、白芸豆提取物、玳玳花粉、桑葚花色苷、茶多糖、菊粉、燕麦葡聚糖、抗性糊精。
其中,岩藻黄质可以激活燃脂因子,减少白色脂肪;白藜芦醇能抑制脂肪细胞生长,调控生热作用、促进脂解和脂肪酸氧化;中链甘油三酯可以激活体内燃脂因子;白芸豆提取物和玳玳花粉含有α-淀粉酶抑制剂,阻断淀粉类物质的吸收,降低热量摄取;桑葚花色苷和茶多糖能抑制脂肪吸收;菊粉和燕麦葡聚糖能增加饱腹感,减少用餐次数和数量;抗性糊精可以增加饱腹感,并作为益生元刺激益生菌的增长,调节肠道菌群,促进健康。
在本发明的优选实施方式中,所述组分的重量份数如下:岩藻黄质33-50份、白藜芦醇5-12份、中链甘油三酯4-10份、白芸豆提取物36-50份、玳玳花粉4-12份、桑葚花色苷27-40份、茶多糖16-28份、菊粉8-22份、燕麦葡聚糖10-28份、抗性糊精18-33份。
在本发明的优选实施方式中,所述组分的重量份数如下:岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份、白芸豆提取物40-45份、玳玳花粉5-10份、桑葚花色苷30-35份、茶多糖18-25份、菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精20-30份。在本发明的优选实施方式中,所述可食用组合物可制成片剂、胶囊剂、口服液、颗粒剂、压片糖果或饮料。
在本发明的进一步优选实施方式中,所述可食用组合物进一步包含辅料和/或添加剂。
在一些优选实施方式中,所述辅料和/或添加剂为矫味剂、填充剂、粘合剂或抗结剂中的任一种或几种。
在另一些优选实施方式中,所述矫味剂为异麦芽酮糖、三氯蔗糖、安赛蜜、甜菊糖苷或糖精钠中的任一种或几种。
在另一些优选实施方式中,所述填充剂为微晶纤维素、甘露糖醇、木糖醇、蔗糖或赤藓糖醇中的任一种或几种。
在另一些优选实施方式中,所述粘合剂为海藻酸钠、聚维酮或聚乙烯醇中的任一种或几种。
在另一些优选实施方式中,所述抗结剂为硬脂酸镁、硬脂酸、二氧化硅或滑石粉中的任一种或几种。
另一方面,本发明提供一种用于减缓肥胖的可食用组合物,优选地,所述可食用组合物制备为4个独立的部分,其中,
A部分包含岩藻黄质33-50份、白藜芦醇5-12份、中链甘油三酯4-10份;
B部分包含白芸豆提取物36-50份、玳玳花粉4-12份;
C部分包含桑葚花色苷27-40份、茶多糖16-28份;
D部分包含菊粉8-22份、燕麦葡聚糖10-28份、抗性糊精18-33份;
其中,A、B、C或D部分以片剂、胶囊剂、口服液、颗粒剂、压片糖果或饮料的制剂形式提供,且各部分的制剂形式相同或不相同。
在本发明的优选实施方式中,所述A部分包含岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份;所述B部分包含白芸豆提取物40-45份、玳玳花粉5-10份;所述C部分包含桑葚花色苷30-35份、茶多糖18-25份;所述D部分包含菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精20-30份。
在本发明的进一步优选实施方式中,所述A部分包含岩藻黄质37、39、40、41、43或45份、白藜芦醇7、8、9或10份、中链甘油三酯5、6、7或8份;所述B部分包含白芸豆提取物40、41、42、43、44或45份、玳玳花粉5、6、7、8、9或10份;所述C部分包含桑葚花色苷30、31、32、33、34或35份、茶多糖18、19、20、21、22、23、24或25份;所述D部分包含菊粉10、12、14、15、16、18或20份、燕麦葡聚糖12.5、15、17.5、20、22.5或25份、抗性糊精20、22、24、25、26、28或30份。
在本发明的进一步优选实施方式中,所述A部分包含岩藻黄质37份、白藜芦醇7份、中链甘油三酯5份;所述B部分包含白芸豆提取物40份、玳玳花粉5份;所述C部分包含桑葚花色苷30份、茶多糖18份;所述D部分包含菊粉10份、燕麦葡聚糖12.5份、抗性糊精20份。
在本发明的进一步优选实施方式中,所述A部分包含岩藻黄质40份、白藜芦醇8份、中链甘油三酯7份;所述B部分包含白芸豆提取物42份、玳玳花粉7份;所述C部分包含桑葚花色苷33份、茶多糖21份;所述D部分包含菊粉15份、燕麦葡聚糖18份、抗性糊精25份。
在本发明的进一步优选实施方式中,所述A部分包含岩藻黄质45份、白藜芦醇10份、中链甘油三酯8份;所述B部分分包含白芸豆提取物45份、玳玳花粉10份;所述C部分包含桑葚花色苷35份、茶多糖25份;所述D部分包含菊粉20份、燕麦葡聚糖25份、抗性糊精30份。
在本发明的优选实施方式中,将所述A部分、B部分、C部分、D部分分别制成片剂。
在本发明的一些实施方式中,所述可食用组合物进一步包含辅料和/或添加剂;优选地,所述辅料和/或添加剂为矫味剂、填充剂、粘合剂或抗结剂中的任一种或几种。
在本发明的优选实施方式中,所述矫味剂为异麦芽酮糖、三氯蔗糖、安赛蜜、甜菊糖苷或糖精钠中的任一种或几种。优选地,所述矫味剂在各部分中的重量份数为30-57份;优选地,所述矫味剂在A部分中的重量份数为30-44份,所述矫味剂在B部分中的重量份数为45-55份,所述矫味剂在C部分中的重量份数为30-50份,所述D矫味剂在部分中的重量份数为30-57份。
在本发明的优选实施方式中,所述填充剂为微晶纤维素、甘露糖醇、木糖醇、蔗糖或赤藓糖醇中的任一种或几种;优选地,所述填充剂在各部分中的重量份数为0-12份。
在本发明的优选实施方式中,所述粘合剂为海藻酸钠、聚维酮或聚乙烯醇中的任一种或几种;优选地,所述粘合剂在各部分中的重量份数为0-5份。
在本发明的优选实施方式中,所述抗结剂为硬脂酸镁、硬脂酸、二氧化硅或滑石粉中的任一种或几种;优选地,所述抗结剂在各部分中的重量份数为0-5。
在本发明的优选实施方式中,所述A部分片剂中包含拮抗剂6-8份,优选地,所述拮抗剂为硬脂酸镁。
在本发明的优选实施方式中,所述C部分片剂中包含填充剂8-12份,优选为微晶纤维素。
在本发明的优选实施方式中,所述D部分片剂中包含粘合剂2.5-5份,抗结剂3-5份,包含填充剂5-7份;优选地,所述粘合剂为海藻酸钠,所述拮抗剂为硬脂酸镁,所述填充剂为微晶纤维素。
在本发明的优选实施方式中,所述可食用组合物制备为4个独立的部分,其中,
所述A部分包含岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份、异麦芽酮糖30-44份、硬脂酸镁6-8份;
所述B部分包含白芸豆提取物40-45份、玳玳花粉5-10份、异麦芽酮糖45-55份;
所述C部分包含桑葚花色苷30-35份、茶多糖18-25份、异麦芽酮糖30-50份、微晶纤维素8-12份;
所述D部分包含菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精30-57份、异麦芽酮糖30-44份、海藻酸钠2.5-5份、硬脂酸镁3-5份、微晶纤维素5-7份;
其中,A、B、C或D部分均为片剂形式。
另一方面,本发明还提供一种制备用于减缓减肥的可食用产品的方法,将上述的A、B、C、D部分分别采用压片法制成4种片剂。在本发明的优选实施方式中,所述压片法采用干法压片,将制得的A片、B片、C片和D片放在同一个包装袋中封口。
另一方面,本发明还提供一种上述组合物在制备缓解肥胖的功能性食品或药物中的用途。
本发明将上述功能原料科学配伍,并通过有效成分之间的协同作用,在增加饱腹感的同时刺激脂肪燃烧、降低热量摄取、减少脂肪吸收,对减缓体重增长、降低血清中的甘油三酯和胆固醇具有协同增效的作用。本发明的产品采用天然活性物质制成,风味良好,天然健康,无毒副作用。
具体实施方式
下面结合实施例对本发明的具体实施方式作进一步描述,本发明的优势和特点将会随着描述而更为清楚。但这些实施例仅是示例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例中未注明具体条件或方法的,均按照常规条件或方法进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
白芸豆提取物:购自西安锐禾生物工程技术有限公司(食品级)
玳玳花粉:购自斯诺特生物陕西斯诺特生物技术有限公司(食品级)
桑葚花色苷:购自山东圣嘉得生物科技有限公司(食品级)
茶多糖、菊粉:购自山东齐鲁生物科技有限公司(食品级)
燕麦葡聚糖:购自河北旺优生物科技有限公司(食品级)
抗性糊精:购自山东瑞帆生物科技有限公司(食品级)
岩藻黄质:购自西安千诺生物有限公司(食品级)
白藜芦醇:购自河南锦发生物科技有限公司(食品级)
中链甘油三酯:购自武汉冠赢生物科技有限公司(食品级)
实施例1、制备压片制剂
(1)片剂A的制备方法:称取表1中重量份的岩藻黄质:白藜芦醇、中链甘油三酯及辅料,采用干法压片(例如,参考“李炳东等.叶黄素酯片(压片糖果)制备工艺优化[J].食品工业,2022,43(09):16-18.”),制得片剂A产品,规格为0.8g/片;
(2)片剂B的制备方法:称取表1中重量份的白芸豆提取物、玳玳花粉及辅料,采用干法压片制得片剂产品,规格为1.0g/片;
(3)片剂C的制备方法:称取表1中重量份的桑葚花色苷、茶多糖及辅料,采用干法压片制得片剂产品,规格为每片1.0g/片;
(4)片剂D的制备方法:称取表1中重量份的菊粉、燕麦葡聚糖、抗性糊精及辅料,采用干法压片制得片剂产品,规格为每片1.0g/片。
将上述4种压片放在同一包装袋中,每包ABCD各1片,包装袋封口,即得压片产品。
表1.各处方的组分和添加量
对比例1:参照表1的对比例成分,制备工艺采用如上所述工艺,分别制备A、B、C、D片剂,获得对比例1的压片产品,作为现有技术对照。对比例1的各成分选择也可参见US9066973B。
实施例2、缓解肥胖的效果试验
采用实施例1的处方2作为本发明可食用组合物的示例。将72只四周龄的雄性C57BL/6J小鼠适应性喂养一周后分为12组,每组6只,所有小鼠按照表2进行分组和饲喂,其中低脂纯化词料(脂肪含量10%,MD10%FAT)、高脂纯化饲料(脂肪含量60%,MD60%FAT)均购自江苏美迪森生物医药有限公司。以组7为例,取ABCD片剂各一片,共同溶于75ml水中,进行小鼠灌胃,0.5ml/只小鼠,一天灌胃一次。其他组别采用类似的方式向小鼠施用,保证各组小鼠摄入的活性成分总量相当。组1和组2则采用0.2mL生理盐水灌胃。实验期间小鼠可自由获得食物和水。
12周后,测定各组小鼠的体重,计算相对于实验前的体重增加量;之后,小鼠被安乐死,取血收集血清,测定血清中甘油三脂和胆固醇的含量,结果如表3所示。
表2.动物实验分组设计
表3.小鼠体重增长量、甘油三酯和胆固醇
不同组间的结果差异用不同字母表示,其中 P<0.05
表3结果显示:
(1)体重增长量:相比于模型组、单片剂组(组3-6)或三片剂组(组8-11),服用本发明的ABCD四个片剂(组7)的小鼠体重增长量显著降低,表明本发明的组合物中,各成分对小鼠减缓体重增长相互之间产生了协同作用。相对于现有技术对照组(组12),服用本发明ABCD片剂后,小鼠体重增加量也显著降低(9.35±0.36 vs 11.23±0.21),表明本发明的组合物相比于现有技术具有更明显的减缓体重增长的作用。
(2)血清中甘油三酯和胆固醇含量:相比于未给药的模型组,服用本发明的ABCD四个片剂(组7)的小鼠血清中甘油三酯和胆固醇含量均明显降低。上述结果表明,本发明的组合物具有显著的降低血清中甘油三酯和胆固醇的作用。
综上所述,本发明的组合物或产品对减缓体重增长、降低血清中的甘油三酯和胆固醇含量具有明显的协同效果,显著优于现有技术中的同类型减肥降脂产品。
以上对本发明具体实施方式的描述并不限制本发明,本领域技术人员可以根据本发明作出替换、变化和修改,只要不脱离本发明的精神,均应属于本发明权利要求保护的范围。本发明的保护范围应以权利要求书所限定的保护范围为准。
Claims (16)
1.一种用于减缓肥胖的可食用组合物,其特征在于,所述组合物包括如下组分:岩藻黄质、白藜芦醇、中链甘油三酯、白芸豆提取物、玳玳花粉、桑葚花色苷、茶多糖、菊粉、燕麦葡聚糖、抗性糊精。
2.根据权利要求1所述的可食用组合物,其特征在于,所述组分的重量份数如下:岩藻黄质33-50份、白藜芦醇5-12份、中链甘油三酯4-10份、白芸豆提取物36-50份、玳玳花粉4-12份、桑葚花色苷27-40份、茶多糖16-28份、菊粉8-22份、燕麦葡聚糖10-28份、抗性糊精18-33份。
3.根据权利要求1所述的可食用组合物,其特征在于,所述组分的重量份数如下:岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份、白芸豆提取物40-45份、玳玳花粉5-10份、桑葚花色苷30-35份、茶多糖18-25份、菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精20-30份。
4.根据权利要求1-3中任一项所述的可食用组合物,其特征在于,所述组合物可制成片剂、胶囊剂、口服液、颗粒剂、压片糖果或饮料。
5.根据权利要求1-4中任一项所述的可食用组合物,其特征在于,所述可食用组合物制备为4个独立的部分,其中,
A部分包含岩藻黄质33-50份、白藜芦醇5-12份、中链甘油三酯4-10份;
B部分包含白芸豆提取物36-50份、玳玳花粉4-12份;
C部分包含桑葚花色苷27-40份、茶多糖16-28份;
D部分包含菊粉8-22份、燕麦葡聚糖10-28份、抗性糊精18-33份;
其中,A、B、C或D部分以片剂、胶囊剂、口服液、颗粒剂、压片糖果或饮料的制剂形式提供,且各部分的制剂形式相同或不相同。
6.根据权利要求5所述的可食用组合物,其特征在于,所述A部分包含岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份;所述B部分包含白芸豆提取物40-45份、玳玳花粉5-10份;所述C部分包含桑葚花色苷30-35份、茶多糖18-25份;所述D部分包含菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精20-30份。
7.根据权利要求5或6所述的可食用组合物,其特征在于,将所述A部分、B部分、C部分、D部分分别制成片剂。
8.根据权利要求1-7任一项所述的可食用组合物,其特征在于,所述可食用组合物进一步包含辅料和/或添加剂;优选地,所述辅料和/或添加剂为矫味剂、填充剂、粘合剂或抗结剂中的任一种或几种。
9.根据权利要求8所述的可食用组合物,其特征在于,所述矫味剂为异麦芽酮糖、三氯蔗糖、安赛蜜、甜菊糖苷或糖精钠中的任一种或几种,优选地,所述矫味剂在各部分中的重量份数为30-57份。
10.根据权利要求8所述的可食用组合物,其特征在于,所述填充剂为微晶纤维素、甘露糖醇、木糖醇、蔗糖或赤藓糖醇中的任一种或几种;优选地,所述填充剂在各部分中的重量份数为0-12份。
11.根据权利要求8所述的可食用组合物,其特征在于,所述粘合剂为海藻酸钠、聚维酮或聚乙烯醇中的任一种或几种;优选地,所述粘合剂在各部分中的重量份数为0-5份。
12.根据权利要求8所述的可食用组合物,其特征在于,所述抗结剂为硬脂酸镁、硬脂酸、二氧化硅或滑石粉中的任一种或几种;优选地,所述抗结剂在各部分中的重量份数为0-5。
13.如权利要求8所述的可食用组合物,其特征在于,所述可食用组合物制备为4个独立的部分,其中,
所述A部分包含岩藻黄质37-45份、白藜芦醇7-10份、中链甘油三酯5-8份、异麦芽酮糖30-44份、硬脂酸镁6-8份;
所述B部分包含白芸豆提取物40-45份、玳玳花粉5-10份、异麦芽酮糖45-55份;
所述C部分包含桑葚花色苷30-35份、茶多糖18-25份、异麦芽酮糖30-50份、微晶纤维素8-12份;
所述D部分包含菊粉10-20份、燕麦葡聚糖12.5-25份、抗性糊精30-57份、异麦芽酮糖30-57份、海藻酸钠2.5-5份、硬脂酸镁3-5份、微晶纤维素5-7份;
其中,A、B、C或D部分均为片剂形式。
14.一种制备用于减缓减肥的可食用产品的方法,其特征在于,将权利要求5-13任一项中所述的A、B、C、D部分分别采用压片法制成4种片剂。
15.根据权利要求14所述的方法,其特征在于,所述压片法采用干法压片,将制得的A片、B片、C片和D片放在同一个包装袋中封口。
16.权利要求1-13任一项所述组合物在制备缓解肥胖的功能性食品或药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310829449.8A CN116849356A (zh) | 2023-07-07 | 2023-07-07 | 一种用于缓解肥胖的可食用组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310829449.8A CN116849356A (zh) | 2023-07-07 | 2023-07-07 | 一种用于缓解肥胖的可食用组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116849356A true CN116849356A (zh) | 2023-10-10 |
Family
ID=88222971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310829449.8A Pending CN116849356A (zh) | 2023-07-07 | 2023-07-07 | 一种用于缓解肥胖的可食用组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116849356A (zh) |
-
2023
- 2023-07-07 CN CN202310829449.8A patent/CN116849356A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2925159B1 (en) | Compositions for balancing gut microbiota and the preparation and the uses thereof | |
EP1312374A1 (en) | Sugar absorption inhibitors and process for producing the same | |
US20110177175A1 (en) | Dietary fiber compositions | |
WO2011101171A1 (en) | Nutritional composition | |
WO2007119837A1 (ja) | リパーゼ阻害剤 | |
WO2006118370A1 (en) | Composition for improving constipation comprising sugar and sugar alcohols | |
WO2005074961A1 (ja) | 体脂肪調整剤 | |
KR20170073293A (ko) | 굴피나무잎, 자작나무수피 또는 차가버섯 추출물을 유효성분으로 하는 폐질환 치료, 개선 또는 예방용 조성물 | |
CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
CN116849356A (zh) | 一种用于缓解肥胖的可食用组合物及其制备方法 | |
CN102688307A (zh) | 一种中药组合物雪山胃宝咀嚼片及其制备方法 | |
TW201936065A (zh) | 腸道屏障功能改善用組成物 | |
Kuchnia et al. | Natural bioactive food components for improving enteral tube feeding tolerance in adult patient populations | |
WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
KR20190080218A (ko) | 당근 발효 식초 제조방법 및 이를 포함하는 비만 예방 또는 개선용 식품 조성물 | |
KR20190001112A (ko) | 흰점박이꽃무지 유충 추출물을 포함하는 항비만 조성물 | |
KR20180118413A (ko) | 밀리타리스 동충하초 부탄올 분획물을 유효성분으로 하는 간암의 예방 또는 치료용 조성물 | |
KR101552282B1 (ko) | 디하이드로진저론을 함유하는 비만 치료 또는 예방용 조성물 | |
KR20050014615A (ko) | 오미자 추출물을 유효성분으로 함유하는 관절염 예방 및치료용 조성물 | |
JP6916422B2 (ja) | 骨吸収抑制用組成物及び骨吸収抑制用食品組成物 | |
WO2018124258A1 (ja) | 慢性疲労症候群の治療剤 | |
CN112353837B (zh) | 葛花提取物及其用途 | |
KR20180118412A (ko) | 밀리타리스 동충하초 에틸아세테이트 분획물을 유효성분으로 하는 간암의 예방 또는 치료용 조성물 | |
KR20130031678A (ko) | 한약재의 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 조성물 | |
KR102474229B1 (ko) | 식물성스테롤(Phytosterols)을 유효성분으로 함유하는 타액 분비 증강 또는 구강건조증 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |